Recombinant type xvii collagen having triple helix structure and use thereof
By optimizing the amino acid sequence of recombinant XVII collagen in E. coli and Pichia expression systems and adding hydroxylase genes to form a triple helical structure, the problem of unmodified and poor stability of recombinant collagen in traditional systems is solved, and the effect of high biological activity and transdermality is achieved.
Patent Information
- Application Number
- PCT/CN2024/095261
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-05-24
- Publication Date
- 2025-07-31
AI Technical Summary
In the prior art, recombinant collagen is not modified after translation in traditional prokaryotic expression systems, does not form a higher triple helix conformation, has low biological activity, poor stability, and the natural collagen has a large molecular weight and is not easy to function transdermally.
A recombinant XVII collagen was designed to optimize the amino acid sequence to form a triple helical structure by expressing the recombinant vector in the E. coli and Pichia expression systems, and the addition of hydroxylase gene fragments to improve protein stability and significantly reduce molecular weight for transdermal purposes.
Recombinant collagen is achieved with high purity and good thermal stability, and has various biological activities such as cell migration. Its molecular weight is significantly smaller than that of natural collagen and can easily penetrate the skin barrier to play a role.